Ozem­pic sales surge could con­tin­ue in­to 2024, re­searchers say

No­vo Nordisk’s di­a­betes treat­ment Ozem­pic could be the drug in­dus­try’s sec­ond-high­est sell­er in 2024, ac­cord­ing to Eval­u­ate’s lat­est fore­cast, as an­a­lysts and physi­cians sig­nal the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER